System degeneration in an MM1-type sporadic Creutzfeldt-Jakob disease case with an unusually prolonged akinetic

Yasushi Iwasaki1, Keiko Mori2, Masumi Ito2

  • 1Department of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University , Nagakute, Japan.

Prion
|January 21, 2021
PubMed

Insights

This study details a rare case of methionine/methionine type 1 sporadic Creutzfeldt-Jakob disease (sCJD) with an extended akinetic mutism phase. Neuropathology revealed system degeneration, highlighting distinct disease progression patterns in this classic sCJD subtype.

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • Sporadic Creutzfeldt-Jakob disease (sCJD) typically progresses rapidly, with methionine/methionine type 1 (MM1-type) sCJD presenting classic clinicopathological features.
  • Patients with MM1-type sCJD usually reach an akinetic mutism state within months and have a poor prognosis without supportive care.

Observation:

  • A 48-year-old Japanese man with MM1-type sCJD exhibited an unusually prolonged akinetic mutism state lasting over two years.
  • Early symptoms included behavioral changes, gait disturbance, and rapid cognitive decline, with diffusion-weighted MRI showing extensive cerebral cortical hyperintensity.
  • Prion protein (PrP) gene analysis confirmed methionine homozygosity at codon 129 without mutations.

Findings:

  • Despite prolonged stability with tube feeding, the patient died 30 months post-onset due to central respiratory failure.
  • Neuropathology revealed severe lesions like status spongiosus, with loss of typical spongiform changes in the neocortex but relative preservation in some areas.
  • Extensive diffuse synaptic-type PrP deposition was observed in the grey matter, alongside conspicuous pyramidal tract degeneration.

Implications:

  • This case underscores that sCJD involves system degeneration with primary, secondary, and preserved regions, even in prolonged cases.
  • The findings suggest a limited survival period for MM1-type sCJD, irrespective of intensive symptomatic treatment.
  • Understanding these distinct pathological patterns is crucial for managing and researching sCJD progression.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.2K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K